CAPN6 Antibody

What is CAPN6 and what are its key biological functions?

CAPN6 is a non-classical member of the calpain protein family that, unlike classical calpains, cannot degrade proteins. It is primarily expressed in fetal muscle and placenta, with expression decreasing after birth but becoming upregulated in various tumor tissues . CAPN6 functions as a microtubule-stabilizing protein involved in:

• Regulation of microtubule dynamics and cytoskeletal organization

• Maintenance of cell stability

• Control of cell movement through interaction with Rho guanine nucleotide exchange factor GEF-H1 to inhibit Rac1GTPase activity

• Inhibition of apoptosis, particularly in cancer cells

• Regulation of autophagy in inflammatory environments

CAPN6 has been implicated in multiple pathological conditions including uterine leiomyomas, osteosarcoma, liver cancer, and certain neurological conditions, making it an important research target .

What detection methods are available for CAPN6 antibodies and what applications are they best suited for?

CAPN6 antibodies can be utilized in multiple experimental applications with varying levels of optimization required:

When selecting an application, consider that CAPN6 detection by immunofluorescence reveals its association with cytoskeletal elements, particularly the actin ring, which is important for understanding its functional localization .

How should I interpret unexpected molecular weights when detecting CAPN6 by Western blot?

When detecting CAPN6 by Western blot, researchers should be aware of potential discrepancies between predicted and observed molecular weights:

• The calculated molecular weight of human CAPN6 is approximately 74.6 kDa

• The observed molecular weight on SDS-PAGE is often around 68 kDa

This discrepancy can be due to:

• Post-translational modifications affecting protein migration

• Protein degradation during sample preparation

• Presence of splice variants with different molecular weights

• Differences in gel composition and running conditions

To address this issue, researchers should:

• Include positive controls with known CAPN6 expression

• Use protein markers that span the range of interest

• Consider performing experiments to verify antibody specificity (e.g., using CAPN6 knockdown or overexpression samples)

• Compare results with multiple antibodies targeting different epitopes of CAPN6

For example, validation experiments shown in search results utilized rat lung tissue lysate with CAPN6 antibody at both 0.5 and 1 μg/mL concentrations to demonstrate consistent detection at the expected molecular weight .

How do I design experiments to investigate CAPN6's role in the Rac1/PAK1 signaling pathway?

To investigate CAPN6's role in the Rac1/PAK1 signaling pathway, a structured experimental approach is recommended:

• Expression manipulation strategies:

  • Knockdown CAPN6 using specific shRNA (e.g., sh1: 5′-GGACCACTGACATTCCTATTA-3′ and sh2: 5′-GGTTCCGTCTTCACCATCTGTA-3′)

  • Overexpress CAPN6 using a mammalian expression vector containing the full CAPN6 cDNA sequence

  • Use lentiviral or retroviral transduction for stable expression manipulation

• Pathway analysis experiments:

  • Measure Rac1 activation state using pull-down assays with PAK-binding domain constructs

  • Assess phosphorylation status of PAK1 using phospho-specific antibodies

  • Examine downstream effectors of the pathway using Western blot

• Functional assays:

  • Cell proliferation using CCK-8 assay following CAPN6 manipulation

  • Apoptosis assessment using flow cytometry with Annexin V/PI staining

  • Cell migration assays to assess cytoskeletal effects

Research has demonstrated that silencing CAPN6 expression results in decreased Rac1 and phospho-PAK1 levels, while upregulated Rac1 expression can reverse the reduced phosphorylation of PAK1 induced by CAPN6 silencing . This connection suggests CAPN6 regulates cell proliferation and apoptosis through this pathway, particularly in uterine leiomyoma cells.

What are the optimal conditions for using CAPN6 antibodies in immunofluorescence studies of cytoskeletal dynamics?

For optimal immunofluorescence studies of CAPN6 and cytoskeletal dynamics:

• Cell preparation:

  • Culture cells on glass coverslips coated with appropriate substrate (e.g., poly-L-lysine, collagen)

  • Consider using cell types with well-defined cytoskeletal structures (e.g., fibroblasts, myoblasts)

  • Include both control and experimental conditions (e.g., CAPN6 overexpression, knockdown)

• Fixation and permeabilization:

  • For optimal preservation of microtubule and actin structures, use 4% paraformaldehyde for 15-20 minutes

  • Permeabilize with 0.1-0.2% Triton X-100 for 5-10 minutes

  • For detailed microtubule visualization, consider methanol fixation at -20°C

• Antibody incubation:

  • Block with 3-5% BSA or appropriate serum for 1 hour

  • Incubate with primary anti-CAPN6 antibody at 20 μg/mL overnight at 4°C

  • For co-localization studies, include antibodies against cytoskeletal markers (e.g., anti-actin, anti-tubulin)

  • Use appropriate fluorophore-conjugated secondary antibodies

• Co-staining strategies:

  • For microtubule stability assessment: co-stain with anti-acetylated tubulin (clone 6-11B-1)

  • For actin co-localization: use phalloidin conjugates with contrasting fluorophores

  • For dynamics studies: consider live-cell imaging with GFP-CAPN6 fusion constructs

Research has shown that CAPN6 localizes to the actin ring, suggesting its involvement in cytoskeletal organization . Additionally, immunofluorescence studies have demonstrated that CAPN6 may regulate autophagy, which can be visualized using GFP-RFP-LC3 constructs to monitor autophagic flux .

How can I effectively use CAPN6 antibodies to study its role in inflammatory environments?

To study CAPN6's role in inflammatory environments using antibodies:

• Experimental model setup:

  • In vitro: Treat myoblasts or relevant cell types with inflammatory cytokine mixture (2 ng/ml IL-6, 2 ng/ml TNF-α, 2 ng/ml INF-γ and 10 ng/ml LPS)

  • In vivo: Consider disease models that feature inflammatory states (e.g., chronic kidney disease models)

• Expression analysis protocol:

  • Measure CAPN6 mRNA levels using RT-qPCR with primers:

    • Forward: 5′-TGT TTG GCT GTT CAG GAG TC-3′

    • Reverse: 5′-TGG GAA GCA AGT CGT CAA TC-3′

  • Compare CAPN6 protein expression using Western blot (dilution 1:1000) between normal and inflammatory conditions

  • Use GAPDH as loading control

• Mechanism investigation:

  • Examine autophagy markers (LC3, p62) in relation to CAPN6 expression

  • Assess mTOR signaling components (mTOR, p-p70s6k1/p70s6k1, p-4EBP1/4EBP1)

  • Use CAPN6 knockdown approaches to determine causality

• Visualization techniques:

  • Employ immunofluorescence to monitor autophagy using LC3 antibodies

  • Consider dual immunofluorescence to co-localize CAPN6 with autophagy markers

Research findings indicate that inflammatory cytokines upregulate CAPN6 expression, which subsequently inhibits autophagy in muscle cells by stabilizing mTOR activity . This mechanism may be relevant in chronic inflammatory conditions such as chronic kidney disease-related muscle atrophy.

How do I validate the specificity of a CAPN6 antibody for my research model?

A comprehensive validation strategy for CAPN6 antibodies should include:

• Expression manipulation controls:

  • Overexpression: Transfect cells with CAPN6 expression vectors (e.g., Flag-tagged CAPN6)

  • Knockdown: Use CAPN6-specific shRNA or siRNA (validated sequences from literature)

  • Compare antibody signals between these conditions using Western blot

• Multiple application verification:

  • Test antibody in at least two different applications (e.g., WB and IF)

  • Compare subcellular localization patterns with published literature

  • Ensure molecular weight is consistent with expected size (~68-74 kDa)

• Cross-reactivity assessment:

  • Test antibody against samples from multiple species if working with non-human models

  • Verify antibody specificity across different tissues with varying CAPN6 expression levels

  • Consider peptide competition assays using the immunizing peptide

• Positive control selection:

  • Use tissues/cells known to express CAPN6 (placenta, embryonic tissues, certain tumor types)

  • Include rat lung tissue lysate, which has been validated for CAPN6 detection

  • For human samples, consider uterine leiomyoma tissue which shows elevated CAPN6 expression

The antibody validation should be documented with clear images showing the expected patterns in both positive and negative control conditions, similar to the validation images provided by manufacturers showing Western blot analysis, immunohistochemistry, and immunofluorescence results .

What are the critical parameters for optimizing CAPN6 detection in protein-protein interaction studies?

For successful protein-protein interaction studies involving CAPN6:

• Immunoprecipitation optimization:

  • Lysis buffer composition: Use 10 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 10% glycerol with protease and phosphatase inhibitors

  • Pre-clearing step: Incubate lysates with protein A/G beads before adding antibodies to reduce non-specific binding

  • Antibody selection: Choose antibodies raised against epitopes not involved in protein interactions

  • Controls: Include IgG isotype controls and input samples

• Co-immunoprecipitation strategy:

  • For tubulin interactions: Use anti-α-tubulin antibody for immunoprecipitation followed by CAPN6 detection

  • For Rac1 pathway components: Consider immunoprecipitating CAPN6 and blotting for GEF-H1, Rac1, or PAK1

  • Cross-linking option: Consider using reversible cross-linkers for transient interactions

• Detection methods:

  • Western blot: Use clean, high-sensitivity detection methods (ECL substrate kit)

  • Mass spectrometry: For unbiased identification of interaction partners

  • Proximity ligation assay: For in situ visualization of protein interactions

• Interaction verification strategies:

  • Reciprocal co-immunoprecipitation (pull down with partner protein, detect CAPN6)

  • Domain mapping using truncated constructs

  • Functional assays to confirm biological relevance of interactions

Research has demonstrated that CAPN6 interacts with tubulin and regulates microtubule stability, which can be assessed through immunoprecipitation with anti-α-tubulin antibody followed by CAPN6 detection . Additionally, CAPN6 may interact with components of the Rac1/PAK1 pathway, affecting cell proliferation and apoptosis .

How does post-translational modification of CAPN6 affect antibody recognition, and how can this be addressed?

Post-translational modifications (PTMs) of CAPN6 can significantly impact antibody recognition:

• Common PTMs affecting CAPN6 detection:

  • Phosphorylation: May alter epitope accessibility or protein conformation

  • Ubiquitination: Can affect protein stability and detection

  • Acetylation: CAPN6 has been associated with acetylated tubulin, suggesting potential regulation through acetylation

  • Proteolytic processing: May generate fragments with altered antibody reactivity

• Experimental approaches to address PTM interference:

  • Use antibodies targeting different epitopes across the CAPN6 protein

  • Compare results from denaturing (Western blot) and non-denaturing (IP, IF) conditions

  • Consider phosphatase treatment of samples to eliminate phosphorylation-dependent effects

  • Use proteasome inhibitors to prevent degradation if ubiquitination is a factor

• Modification-specific detection strategies:

  • Employ phospho-specific antibodies if studying CAPN6 regulation by phosphorylation

  • Use co-immunoprecipitation with anti-ubiquitin antibodies to assess ubiquitination status

  • Consider mass spectrometry to map specific modification sites

• Interpretation guidelines:

  • Multiple bands on Western blot may indicate different modification states

  • Shifts in apparent molecular weight may reflect PTMs

  • Changes in antibody reactivity under different cellular conditions may indicate modification-dependent epitope masking

While specific information on CAPN6 PTMs is limited in the provided search results, research indicates that CAPN6 functions are regulated in response to various stimuli, suggesting potential PTM-dependent regulation. For example, inflammatory cytokines upregulate CAPN6 expression and may affect its post-translational state , which could impact antibody recognition.

Applications in Disease Research

For investigating CAPN6's role in muscle development and disease:

• Developmental expression analysis:

  • Track CAPN6 expression during different stages of muscle development using:

    • RT-qPCR for mRNA expression with validated primers

    • Western blot for protein expression (1:1000 dilution)

    • Immunohistochemistry for spatial distribution in developing muscle tissues

• Muscle disease model protocols:

  • For inflammatory muscle conditions:

    • Treat myoblasts with cytokine mixture (2 ng/ml IL-6, 2 ng/ml TNF-α, 2 ng/ml INF-γ, 10 ng/ml LPS)

    • Analyze CAPN6 expression and correlation with disease markers

  • For chronic kidney disease-related muscle atrophy:

    • Use appropriate animal models that mimic human disease

    • Assess body weight, muscle mass, cross-sectional area, and blood biomarkers

• Mechanistic investigation approaches:

  • Study CAPN6's effect on autophagy:

    • Monitor LC3 and p62 expression by Western blot

    • Use RFP-GFP-LC3 plasmid transfection to assess autophagic flux

  • Examine mTOR signaling:

    • Assess phosphorylation of key components (p70s6k1, 4EBP1)

    • Correlate with CAPN6 expression and autophagy markers

• Functional assays:

  • Myoblast differentiation assessment following CAPN6 manipulation

  • Muscle regeneration analysis in models with altered CAPN6 expression

Research indicates that CAPN6 deficiency promotes skeletal muscle development and regeneration, while its expression is upregulated in inflammatory conditions, inhibiting autophagy and potentially contributing to muscle atrophy . The connection between CAPN6, autophagy inhibition, and mTOR signaling suggests a potential intervention target for muscle disorders.

How can I design experiments to elucidate the contradictory roles of CAPN6 in different disease contexts?

To address the contradictory roles of CAPN6 across different disease contexts:

• Comparative expression profiling:

  • Utilize the same antibody and conditions across different disease models

  • Perform both mRNA (RT-qPCR) and protein (Western blot) analyses

  • Compare subcellular localization patterns using immunofluorescence (20 μg/mL)

  • Create a standardized expression profile across multiple tissue/disease types

• Context-specific signaling pathway analysis:

  • Design experiments to simultaneously assess multiple pathways:

    • Rac1/PAK1 pathway (relevant in uterine leiomyomas)

    • PI3K/AKT pathway (important in cervical and liver cancer)

    • mTOR signaling (significant in autophagy regulation)

    • EDN-1/ERK1/2 and NF-κB pathways (implicated in osteosarcoma)

• Tissue-specific function investigation:

  • Develop tissue-specific knockdown/overexpression models

  • Compare effects of identical CAPN6 manipulations across different cell types

  • Use conditional expression systems to control timing and context of expression

• Resolution strategies for contradictory findings:

  • Investigate cofactor requirements that may differ between tissues

  • Assess post-translational modifications in different contexts

  • Examine splice variants that may have tissue-specific expression

  • Consider protein-protein interactions unique to specific cell types

For example, while CAPN6 inhibits autophagy in inflammatory environments through mTOR signaling , it promotes uterine leiomyoma cell proliferation via the Rac1/PAK1 pathway . These seemingly distinct functions may reflect tissue-specific regulatory mechanisms or interaction partners that modify CAPN6's activity in different cellular environments.

A comprehensive experimental design would include parallel studies in multiple cell types using standardized methods to directly compare CAPN6's function and regulatory mechanisms across contexts, potentially revealing the underlying basis for its diverse roles.

What are the common technical issues when using CAPN6 antibodies and how can they be resolved?

Common technical challenges with CAPN6 antibodies and their solutions:

• High background in immunohistochemistry/immunofluorescence:

  • Problem: Non-specific binding resulting in high background

  • Solutions:

    • Optimize blocking conditions (increase BSA concentration to 3-5%)

    • Reduce primary antibody concentration below recommended 2.5 μg/mL for IHC-P

    • Extend washing steps (3-5 washes of 5-10 minutes each)

    • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce non-specific binding

    • Consider using different blocking agents (normal serum matched to secondary antibody host)

• Inconsistent Western blot detection:

  • Problem: Variable band intensity or multiple bands

  • Solutions:

    • Ensure consistent protein loading with appropriate controls (GAPDH)

    • Optimize transfer conditions for high molecular weight proteins

    • Test multiple antibody concentrations between 0.5-1 μg/mL

    • Use fresh samples and avoid repeated freeze-thaw cycles

    • Consider using gradient gels for better resolution

• Poor immunoprecipitation efficiency:

  • Problem: Weak or no CAPN6 pull-down

  • Solutions:

    • Modify lysis buffer components (10 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 10% glycerol)

    • Pre-clear lysates with protein A/G beads

    • Increase antibody amount or incubation time

    • Cross-link antibody to beads to prevent co-elution

    • Consider using tagged CAPN6 constructs for difficult interactions

• Species cross-reactivity issues:

  • Problem: Antibody doesn't work in non-human samples

  • Solutions:

    • Verify the antibody is validated for your species of interest

    • Check epitope conservation across species

    • Select antibodies specifically validated in multiple species (Human, Mouse, Rat)

    • Consider using species-specific antibodies for critical experiments

Proper storage and handling of CAPN6 antibodies is crucial: store at 4°C for up to three months or -20°C for up to one year, and avoid repeated freeze-thaw cycles . Always include appropriate positive and negative controls in each experiment.

How can I optimize CAPN6 antibody-based assays for detecting low expression levels in clinical samples?

To optimize detection of low CAPN6 expression levels in clinical samples:

• Sample preparation enhancements:

  • Implement efficient protein extraction methods:

    • For tissues: Use RIPA buffer with protease/phosphatase inhibitors

    • For paraffin-embedded sections: Optimize antigen retrieval conditions

  • Concentrate proteins using immunoprecipitation before analysis

  • Consider subcellular fractionation to enrich compartments with higher CAPN6 concentration

• Signal amplification strategies:

  • For Western blot:

    • Use high-sensitivity ECL substrate kits

    • Employ biotin-streptavidin amplification systems

    • Increase exposure time while minimizing background

    • Consider digital imaging systems with accumulating signal capability

  • For immunohistochemistry/immunofluorescence:

    • Utilize tyramide signal amplification

    • Apply polymer-based detection systems

    • Consider multiple-layer antibody approaches (primary → secondary → tertiary)

• Assay platform selection:

  • For quantitative needs: ELISA-based detection with sandwich double-antibody technique

    • Provides superior sensitivity through enzyme amplification

    • Allows accurate quantification with standard curves

  • For spatial information: Proximity ligation assay

    • Offers single-molecule detection capability

    • Provides spatial context in tissue samples

• Protocol adaptations:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Reduce washing stringency slightly to preserve low-abundance signals

  • Use concentrated antibody solutions within validated ranges

  • Include positive controls with known CAPN6 expression levels

The selection of highly sensitive detection systems is particularly important for clinical samples where CAPN6 expression may be heterogeneous or limited to specific cell populations. ELISA-based methods may be particularly valuable as they can detect CAPN6 in heavily diluted samples, with sensitivity often in the pg/mL range .

How can CAPN6 antibodies be used in studying its potential as a therapeutic target?

For investigating CAPN6 as a therapeutic target:

• Target validation approaches:

  • Expression correlation studies:

    • Compare CAPN6 levels between normal and disease tissues using IHC-P (2.5 μg/mL)

    • Correlate expression with disease progression and outcomes

  • Functional validation:

    • Use CAPN6 knockdown models with validated shRNA sequences

    • Assess phenotypic effects relevant to the disease (proliferation, apoptosis, etc.)

    • Examine pathway modulation following CAPN6 manipulation

• Mechanism identification protocols:

  • Pathway-specific analyses:

    • For tumors: Assess Rac1/PAK1, PI3K/AKT, EDN-1/ERK1/2 pathways

    • For inflammatory conditions: Examine mTOR signaling and autophagy markers

  • Interaction partner identification:

    • Perform immunoprecipitation with CAPN6 antibodies to identify binding partners

    • Use proximity labeling approaches for in vivo interaction mapping

    • Validate interactions with co-localization studies using immunofluorescence (20 μg/mL)

• Therapeutic response assessment:

  • Develop cell-based assays to screen potential CAPN6 inhibitors

  • Use CAPN6 antibodies to monitor target engagement following treatment

  • Establish pharmacodynamic markers based on CAPN6 pathway activity

• Translational considerations:

  • Design experiments with disease-specific contexts in mind

  • For oncology applications: Focus on pathways implicated in specific tumor types (see table in Q4.1)

  • For inflammatory/muscle disorders: Focus on autophagy and mTOR regulation

CAPN6 has been identified as a potential therapeutic target in several contexts, including as an HIV dependency factor and in various cancers where its overexpression promotes tumorigenesis . Research suggests that targeting CAPN6 may inhibit tumor growth, enhance apoptosis sensitivity, and potentially modulate inflammatory responses by affecting autophagy regulation .

What novel applications are emerging for CAPN6 antibodies in single-cell analysis techniques?

Emerging applications for CAPN6 antibodies in single-cell analysis:

• Single-cell protein expression profiling:

  • Mass cytometry (CyTOF) applications:

    • Metal-conjugated CAPN6 antibodies for high-dimensional analysis

    • Simultaneous assessment of CAPN6 with pathway components (Rac1, PAK1, mTOR)

    • Correlation with cell-type specific markers

  • Imaging mass cytometry:

    • Spatial distribution of CAPN6 in tissue sections at single-cell resolution

    • Co-localization with cytoskeletal elements and signaling proteins

    • Tumor heterogeneity assessment for precision medicine applications

• Spatial transcriptomics integration:

  • Combined IF/RNA-seq approaches:

    • CAPN6 protein detection with antibodies alongside spatial transcriptomics

    • Correlation between protein expression and transcript levels

    • Identification of post-transcriptional regulation mechanisms

  • In situ sequencing with protein detection:

    • Multiplex RNA detection with CAPN6 protein visualization

    • Analysis of CAPN6 regulation at the single-cell level

• Live-cell dynamics investigation:

  • Antibody fragment applications:

    • Development of cell-permeable antibody fragments for live-cell imaging

    • Monitoring dynamic changes in CAPN6 localization during cell division or migration

  • Proximity sensors:

    • FRET-based sensors using CAPN6 antibody fragments

    • Real-time monitoring of CAPN6 interactions with binding partners

• Microfluidic single-cell analysis:

  • Antibody-based capture of CAPN6-expressing cells

  • Single-cell Western blot for CAPN6 detection

  • Correlation of CAPN6 expression with functional cellular outputs

These emerging applications can provide unprecedented insights into CAPN6 biology by revealing cell-to-cell variability in expression and function, particularly important in heterogeneous tissues such as tumors where CAPN6 has been implicated in disease progression . Single-cell approaches could help resolve contradictory findings about CAPN6 function by identifying cell-type specific effects that may be masked in bulk analyses.

How might recent advances in structural biology inform the development of more specific CAPN6 antibodies?

Structural biology insights for developing superior CAPN6 antibodies:

• Epitope selection based on structural data:

  • Target unique structural regions:

    • Identify CAPN6-specific domains that differ from other calpain family members

    • The C-terminal region of CAPN6 lacks homology to the calmodulin-like domain of other vertebrate calpains

    • Focus on regions that are surface-exposed and not involved in critical interactions

  • Conformational epitope targeting:

    • Develop antibodies recognizing specific CAPN6 conformational states

    • Select epitopes that distinguish active vs. inactive states

    • Consider regions involved in microtubule binding for function-blocking antibodies

• Structure-guided antibody engineering:

  • Complementarity-determining region (CDR) optimization:

    • Use structural data to guide CDR modifications for enhanced specificity

    • Design antibodies with reduced cross-reactivity to other calpain family members

    • Improve affinity through structure-based mutations

  • Format innovations:

    • Develop bispecific antibodies targeting CAPN6 plus interacting partners

    • Create domain-specific antibodies for particular functions (e.g., microtubule binding)

    • Engineer smaller antibody formats for improved tissue penetration

• Post-translational modification awareness:

  • Map modification sites through structural analysis

  • Develop modification-specific antibodies (e.g., phospho-specific)

  • Design antibodies that recognize CAPN6 regardless of modification state

• Functional region targeting:

  • Identify structural regions involved in:

    • Rac1/PAK1 pathway regulation

    • mTOR signaling interaction

    • Microtubule dynamics regulation

    • Develop antibodies specifically targeting these functional domains

CAPN6 has been described as a microtubule-stabilizing protein that regulates cytoskeletal organization . Understanding the structural basis of these interactions could enable the development of highly specific antibodies that not only detect CAPN6 but potentially modulate its function, providing valuable tools for both research and therapeutic applications. Current immunogens, such as the 18 amino acid synthetic peptide from near the carboxy terminus of human CAPN6 , could be refined based on structural insights to yield antibodies with enhanced specificity and functional capabilities.